title: Can systems biology approach help in finding more effective treatment for acute myeloid leukemia?
abstract: Acute myeloid leukemia (AML) is a hematological cancer comprising of cancer stem cells (CSCs) that are responsible for the disease progression, drug resistance and post treatment relapses. Advances in genomic technologies have identified AML as a genetically heterogenous disease with dysregulated gene expression networks. Furthermore, observation of intracellular signaling in individual CSCs by mass cytometry has demonstrated the dysregulation of the mitogen associated protein kinase (MAPK) pathways. It has been envisaged that the future treatment for AML would entail upon formulating individualized treatment plans leading to decreased drug related toxicities for patients. However the emerging role of signaling pathways as dynamic molecular switches influencing the cell cycle process, thereby leading to varying stages of cell differentiation, is making community rethink about the current strategies used for the treatment of AML. This commentary will focus on discovering novel biomarkers and identifying new therapeutic targets, to analyze and treat AML, on a platform enabled by systems biology approach.
authors.affiliation: Symbiosis School of Biomedical Sciences (SSBS), Symbiosis International University (SIU), Lavale, Mulshi, Pune, 412115 Maharashtra India.
authors.forename: Anuradha
authors.initials: A
authors.lastname: Vaidya
keywords: Acute myeloid leukemia; Cancer stem cells; Leukemic stem cells; Mitogen associated protein kinase pathways; Restriction point control